Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news

Show

From To
START study shows that people starting HIV treatment earlier have better quality of life

Rather than treatment side-effects having a negative impact on people’s quality of life when they start HIV treatment, data from the large randomised START study show a

Published
07 March 2016
By
Roger Pebody
TAF/emtricitabine maintains viral suppression as well as TDF regimens with less bone and kidney toxicity

A fixed-dose coformulation of tenofovir alafenamide (TAF) and emtricitabine (FTC, Emtriva), combined with a variety of third antiretroviral agents, maintained undetectable viral load in people who switched

Published
25 February 2016
By
Liz Highleyman
Gilead announces results from first study to evaluate switching to FTAF-based regimens from Truvada® (FTDF)-based regimens

Investigational F/TAF-based regimens demonstrate high rates of virologic suppression and improved renal and bone laboratory parameters compared to Truvada-based regimens.

Published
24 February 2016
From
Gilead press release
Bone density recovers quickly after stopping PrEP

Bone mineral density recovers within six months of stopping pre-exposure prophylaxis (PrEP) containing tenofovir, Bob Grant of the University of California, San Francisco reported on behalf of

Published
24 February 2016
By
Keith Alcorn
Tenofovir treatment raises the risk of broken bones

Treatment containing tenofovir is associated with a higher risk of bone fractures in people living with HIV, but a single infusion of zoledronic acid, a drug used in

Published
23 February 2016
By
Keith Alcorn
People taking a large number of non-HIV-related medications more likely to stop or change HIV drugs

HIV-positive patients who are taking a large number of medications for the treatment of non-HIV-related conditions are at increased risk of stopping or changing their antiretroviral therapy (ART),

Published
27 January 2016
By
Michael Carter
D:A:D study: long-term treatment with tenofovir associated with increased risk of serious liver disease

Long-term therapy with the antiretroviral drug tenofovir increases the risk of end-stage liver disease and liver cancer, according to data from the D:A:D study published

Published
21 January 2016
By
Michael Carter
Viread (Tenofovir, TDF) Linked With Liver Disease and Cancer

Long-term use of Viread (tenofovir disoproxil fumarate, or TDF) is associated with an increased risk of end-stage liver disease (ESLD) as well as hepatocellular carcinoma (HCC, the most common form of liver cancer) among people with HIV.

Published
14 January 2016
From
Poz
Short- or Medium-Term PrEP Is Safer Than Aspirin

Truvada as pre-exposure prophylaxis (PrEP) against HIV has comparable safety to aspirin, at least for the short- and medium-term.

Published
13 January 2016
From
AIDSMeds
South African Medicines Agency approves PrEP

The South African Medicines Control Council (MCC) has approved PrEP. So far it has issued a brief statement, saying that on 28 November it "Approved the use of the fixed-dose combination of tenofovir disoproxyl fumarate and emtricitabine to include pre-exposure prophylaxis of HIV(also referred to as PrEP)." The MCC names the separate drugs rather than Truvada, as South Africans take generic versions of the drugs made on licence locally. The MCC does not recommend criteria for PrEP access or name specific populations but instead soliticts applications from organisations that wish to provide PrEP. Its one stipulation is that, since using the drugs for prevention is a new field, records of adverse events in people offered PrEP should be kept by providers.

Published
08 December 2015
From
South African MCC
← First12345...74Next →

Filter by country